BCM
DYN icon

Bridgeway Capital Management’s Dyne Therapeutics DYN Stock Holding History

Bridgeway Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,400
Closed -$120K – 1405
2023
Q1 		$120K Hold
10,400
– – ﹤0.01% 1202
2022
Q4 		$121K Hold
10,400
– – ﹤0.01% 1193
2022
Q3 		$132K Sell
10,400
-6,000
-37% -$68.8K ﹤0.01% 1221
2022
Q2 		$113K Buy
+16,400
New +$113K ﹤0.01% 1205

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bridgeway Capital Management's DYN Position: Q2 2023 in Review

Bridgeway Capital Management sold out of Dyne Therapeutics (DYN) in Q2 2023, closing a stake of 10,400 shares — an estimated $120K sold.

Bridgeway Capital Management first reported a position in DYN in Q2 2022 and held it in 4 quarters. The position peaked at $132K in Q3 2022. 118 funds tracked by Wall St. Rank hold DYN as of Q2 2023.

  • Bridgeway Capital Management reported no remaining Dyne Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Bridgeway Capital Management sold 10,400 Dyne Therapeutics shares in Q2 2023, an estimated $120K.
  • Bridgeway Capital Management first reported a position in Dyne Therapeutics in Q2 2022 and held it in 4 quarters.
  • Bridgeway Capital Management's Dyne Therapeutics position peaked at $132K in Q3 2022.
  • 118 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2023.

Based on Bridgeway Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.